Home / Acne / High-dose isotretinoin restrains acne relapse

High-dose isotretinoin restrains acne relapse

Major finding: The rate of relapse was 27% in patients whose cumulative dose of isotretinoin exceeded 220 mg/kg and 47% in patients with a cumulative dose below 220 mg/kg (P = .029).

Data source: A prospective, observational intervention study of 116 patients with treatment-resistant nodulocystic acne.

Disclosures: Dr. Stamey reported having no relevant financial disclosures.

MILWAUKEE– Boosting cumulative isotretinoin doses above 220 mg/kg significantly reduced the risk of relapse without dramatically increasing side effects in patients with severe, treatment-resistant nodulocystic acne in a prospective, observational study.

During the 12-month study, 27% of patients who received more than 220 mg/kg and 47% of those who received less than 220 mg/kg had a relapse, defined as treatment with another prescription acne medicine (P = .029).

The number of patients needing retreatment with isotretinoin was similar in both groups (2 vs. 0; P = .31), Mr. Christopher Stamey reported at the annual meeting of the Society for Pediatric Dermatology.

Full Article

About Dr. J. Kim

Dr Kim developed (and is continuing to develop) dermatology research news as we way from dermatologists to stay on top of the latest advances in the field of dermatology.

Check Also

Isolation and Identification of the Follicular Microbiome: Implications for Acne Research.

DOI: j.jid.2018.02.038  PMID: 29548797   Our understanding of the microbiome and the role of P. acnes in …

Leave a Reply

Your email address will not be published. Required fields are marked *